U.S. markets close in 1 hour 26 minutes
  • S&P 500

    4,412.81
    -10.34 (-0.23%)
     
  • Dow 30

    34,854.60
    -261.80 (-0.75%)
     
  • Nasdaq

    14,803.05
    +41.76 (+0.28%)
     
  • Russell 2000

    2,201.78
    -21.81 (-0.98%)
     
  • Crude Oil

    68.27
    -2.29 (-3.25%)
     
  • Gold

    1,814.70
    +0.60 (+0.03%)
     
  • Silver

    25.49
    -0.09 (-0.36%)
     
  • EUR/USD

    1.1840
    -0.0028 (-0.24%)
     
  • 10-Yr Bond

    1.1790
    +0.0030 (+0.26%)
     
  • GBP/USD

    1.3892
    -0.0023 (-0.17%)
     
  • USD/JPY

    109.4840
    +0.4340 (+0.40%)
     
  • BTC-USD

    39,578.87
    +1,675.79 (+4.42%)
     
  • CMC Crypto 200

    973.74
    +46.97 (+5.07%)
     
  • FTSE 100

    7,123.86
    +18.14 (+0.26%)
     
  • Nikkei 225

    27,584.08
    -57.75 (-0.21%)
     

Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows

·1 min read
  • Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-developed with Astellas Pharma (OTCMKTS: ALPMF)

  • The data were presented at the American Society for Cell and Gene Therapy (ASGCT) meeting.

  • Data Highlights:

    • HiTs are CD8 and HLA-independent and kill mesothelin expressing human tumor cells.

    • Data demonstrate that the mesothelin HiT is not dependent on CD8 to kill target cells, and CD4 cells expressing the HiT are cytotoxic towards tumor cells.

    • Data from additional in vitro experiments show that Adaptimmune's HiT is not neutralized by soluble mesothelin, unlike the TRuC construct.

    • HiT T-cells targeting mesothelin induced complete tumor regression in a mouse xenograft tumor model and outperformed a comparator TRuC construct.

  • Price Action: ADAP shares are up 2.1% at $4.82 during the market trading session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.